Hengrui Pharmaceuticals' "Selaishibu Capsule" first imitation approved for listing

Ceresib is a nonsteroidal anti-inflammatory drug that selectively inhibits COX-2 and is mainly used to relieve symptoms and signs of osteoarthritis, rheumatoid arthritis and severe syllaphylistins, as well as to treat acute pain in adultsThe original drug was approved by the U.SFDA in 1998, is the world's first selective nonsteroidal anti-inflammatory analgesic, successfully solved the traditional nonsteroidal anti-inflammatory analgesic stoic sin of the difficult problem, has been described as a "milestone breakthrough."Hengrui Pharmaceutical Serexibu capsules submitted to the State Drug Administration in July 2017 for registration, in November 2017 by the State Drug Administration was included in the priority review, is the first imitation approved for listing, as a result of the adoption of a consistency evaluationin the clinical treatment of arthritis hot drug exibus products, in addition to the approved Ceresibu capsules, Hengrui Pharmaceuticals as early as 2011 has an independent research and development of a new class of new drug Ayrexib listedIn the future, Hengrui Pharma will further expand and improve the layout of product pipelines, based on independent innovation, independent research and development and high-end imitation, promote high-end preparations to achieve import substitution, solve drug accessibility problems, and better benefit patients.